Oncolys BioPharma, Inc. (JP:4588) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncolys BioPharma Inc. has completed enrollment for a Phase I clinical trial evaluating the safety and efficacy of their immunotherapy drug, Telomelysin (OBP-301), in advanced esophageal or gastro-esophageal cancer patients ineligible for surgery. This trial involves a combination of Telomelysin with chemoradiation and follows successful preliminary results in Japan, where Oncolys plans to submit a New Drug Application by end of 2024. The study’s completion marks a significant step towards potential new treatment options for these cancer patients.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money